Poseida Therapeutics Brings In Amgen’s Kerry Ingalls as COO

Poseida Therapeutics said Thursday that Kerry Ingalls has joined the company as its chief operating officer, and that he is tasked with overseeing its global manufacturing operations. Ingalls most recently oversaw clinical and commercial manufacturing for Amgen (NASDAQ: [[ticker:AMGN]]) at its headquarters in Thousand Oaks, CA; he has also held leadership roles at other Amgen sites in the US, in Ireland, and in Puerto Rico, according to Poseida. The San Diego-based biotech company is developing CAR-T cell therapies to treat multiple myeloma, a cancer of the bone marrow, and other forms of cancer. It also aims to develop gene therapies for orphan diseases.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.